Dual Orexin Receptor Antagonists (DORAs) in the Same Class as Belsomra
Belsomra (suvorexant) belongs to the dual orexin receptor antagonist (DORA) class, and there are currently three other FDA-approved drugs in this same family: lemborexant, daridorexant, and the newly emerging vornorexant 1, 2, 3.
Currently Available DORAs
The DORA class works by blocking both orexin-1 (OX1R) and orexin-2 (OX2R) receptors, which suppresses the wake-promoting orexin signaling system 1, 4. All drugs in this class share the same fundamental mechanism of action—antagonizing the binding of wake-promoting neuropeptides orexin A and orexin B to their receptors 1.
The Four DORAs:
- Suvorexant (Belsomra) - First approved DORA 5
- Lemborexant - Second approved DORA 6, 3
- Daridorexant - Third approved DORA 7, 3
- Vornorexant - Newest DORA, recently submitted for approval with notably shorter half-life 2, 3
Key Distinguishing Feature: Elimination Half-Life
The primary pharmacokinetic difference between these DORAs is their elimination half-life, which determines duration of action and risk of next-day residual effects 2, 3. Vornorexant was specifically designed to have the shortest half-life among existing DORAs—comparable to zolpidem—with rapid absorption to minimize next-day somnolence while maintaining efficacy throughout the night 3.
Shared Characteristics Across the DORA Class
All DORAs share similar:
- Metabolism pathway: Primarily metabolized by CYP3A enzymes 7
- Drug interactions: Require dose adjustments with CYP3A inhibitors/inducers 1, 7
- Safety profile: Low abuse potential compared to benzodiazepines and Z-drugs, minimal physical dependence or withdrawal risk 6
- Adverse effects: Dose-dependent somnolence as the primary side effect 5, 2
- FDA warnings: Cognitive/behavioral changes, complex sleep behaviors, and driving impairment 5, 1
Clinical Implications
The expanding DORA class now offers clinicians a broader spectrum of pharmacokinetic profiles to match individual patient sleep complaints 2. Patients with sleep-onset insomnia may benefit from shorter-acting agents like vornorexant, while those with sleep-maintenance insomnia may require longer-acting options like suvorexant or lemborexant 3.
All DORAs demonstrated efficacy in improving sleep outcomes in clinical trials, though with small absolute effect sizes and moderate-strength evidence 5. The American College of Physicians guideline notes that suvorexant improved short-term global and sleep outcomes compared to placebo, with similar findings expected across the DORA class 5.